We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer (RAD 1805)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04298983
Recruitment Status : Recruiting
First Posted : March 6, 2020
Last Update Posted : March 21, 2022
Information provided by (Responsible Party):
Eddy Yang, University of Alabama at Birmingham

Brief Summary:
This Phase II study is designed to study the clinical and radiologic response, as well as, safety and tolerability of abemaciclib in combination with androgen deprivation therapy (ADT) in patients with localized high-risk or locally advanced prostate cancer who are eligible for definitive radiation therapy (RT) and androgen deprivation therapy (ADT).

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Abemaciclib 150 MG by mouth twice daily Drug: Androgen deprivation therapy (ADT) Radiation: Radiation Therapy Phase 2

Detailed Description:

A similar hormone-driven cancer akin to breast cancers is prostate cancer. These tumors are driven by androgen receptor signaling, and CDK4/6 has also been found to be a bona fide target pre-clinically for advanced prostate cancer cell models. Moreover, CDK4/6 inhibition can act as a radiation sensitizer through its effects on the DNA damage response and interactions with cell cycle pathway proteins. For example, it has been found that expression of DNA repair proteins can be regulated by E2F, a transcription factor necessary for the G1 to S phase transition. Also, cyclin D1 has been found to exert a direct role in DNA repair. Lastly, CDK4/6 inhibition has been found to modulate the DNA damage response. These data support the use of CDK4/6 inhibitors as a modulator of DNA damage to enhance sensitivity to radiation.

Given the role of CDK4/6 in tumor resistance to endocrine therapy, in activation of the DNA damage response, and in promoting radiation resistance, we hypothesize that the targeting of CDK4/6 with abemaciclib will enhance the cytotoxicity in combination with blockade of the androgen receptor pathway. Therefore, we propose a pilot phase II investigator initiated trial in patients with high-risk prostate cancer testing the tolerability and toxicity of abemaciclib in combination with ADT.

Patients will receive ADT for 2 years and will start 3 months before radiation therapy. Abemaciclib will start with initiation of ADT and pause 2 weeks prior to start of radiation therapy. Abemaciclib will resume with the first ADT administration post-radiation, which is about 1 month post radiation therapy. Abemaciclib and ADT will continue for a total ADT period of 24 months. Patients will receive study treatment until development of toxicity or disease progression on treatment or any reasons of withdrawal or a maximum of 24 months of therapy with ADT. Patients are seen every 4 weeks with laboratory evaluation. For toxicity or adverse events, patients will undergo labs, physical examination and grades of toxicities will be determined using NCI CTCAE version 4.03.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Clinical Trial of Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer
Actual Study Start Date : February 25, 2021
Estimated Primary Completion Date : April 2023
Estimated Study Completion Date : April 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Abemaciclib

Arm Intervention/treatment
Experimental: Abemaciclib + ADT+ RT
Abemaciclib at 150 mg by mouth twice daily, androgen deprivation therapy (ADT), and radiation therapy in conjunction with ADT.
Drug: Abemaciclib 150 MG by mouth twice daily
Abemaciclib will start with initiation of ADT, 3 months before RT, and pause 2 weeks prior to start of RT. Abemaciclib will resume with the first ADT administration post-radiation, which is about 1 month post radiation therapy. Abemaciclib will continue for a total of 24 months.

Drug: Androgen deprivation therapy (ADT)
ADT will be given every 3 months. ADT and Abemaciclib will pause 2 weeks prior to start of RT. ADT administration will resume with Abemaciclib post-radiation, which is about 1 month post radiation therapy. ADT will continue for a total of 24 months.

Radiation: Radiation Therapy
RT will start 3 months after initiation of ADT and Abemaciclib. RT will be given as standard of care- 180 cGy x 28 fractions to the whole pelvis and the prostate will receive 250 cGy x 28 fractions. After RT is completed, both ADT and Abemaciclib will resume and continue for 24 months.

Primary Outcome Measures :
  1. Clinical Response Rates [ Time Frame: Baseline to 24 months ]
    Clinical response rates will be assessed by percentage of patients who achieve the PSA nadir levels of < 0.5ng/ml on treatment

Secondary Outcome Measures :
  1. PSA declines prior to radiotherapy [ Time Frame: Up to 3 months of treatment ]
    PSA declines prior to radiotherapy- calculated from nadir level prior to initiation of radiation therapy

  2. Time to PSA Failure [ Time Frame: Baseline up to 24 months ]
    Time to PSA failure will be analyzed using the Kaplan-Meier method

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed (core biopsy proven) adenocarcinoma of prostate, localized high-risk or locally advanced.
  • One of the below:

    • Gleason 7-8, any T-stage, and PSA > 20,
    • Gleason 8, ≥ T2, any PSA,
    • Gleason 9-10, any T-stage, any PSA
  • Available biopsy of primary tumor or resected tumor specimen with adequate samples.
  • Prior treatment with systemic anti-cancer agents is not allowed.
  • ECOG PS=0 or 1.
  • Must have at least 1 target lesion.
  • Adequate hematologic and end-organ function:

    • ANC ≥ 1500/mm3
    • Platelet count ≥ 100,000/mm3
    • Hb ≥ 9g/dl
    • Creatinine ≤ ULN or Creatinine Clearance (CrCl) ≥ 60 ml/min
    • Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert syndrome, who can have total Bilirubin > 2.0 x ULN and direct bilirubin within normal limits are permitted).
    • AST, ALT and alkaline phosphatase ≤ ULN
  • Agreement to remain abstinent or use appropriate contraception.
  • Willingness and ability to consent for self to participate in study.
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

  • Prior treatment to CDK4-6 inhibitor.
  • Prior treatment with systemic agents or radiation treatment for the primary cancer.
  • Major surgical procedure or significant traumatic injury within 4 weeks prior to study treatment, and must have fully recovered from any such procedure.
  • Personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
  • Angina, myocardial infarction (MI), symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack (TIA), arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) within 6 months prior to study treatment.
  • Known active viral or non-viral hepatitis or cirrhosis.
  • Any active infection requiring systemic treatment, positive tests for Hepatitis B surface antigen or Hepatitis C ribonucleic acid (RNA).
  • Known history of AIDS (acquired immunodeficiency syndrome)-defining illness.
  • Patients must be surgically sterile or must agree to use effective contraception during the study treatment (including temporary breaks from treatment), and for at least 180 days after stopping last dose of Abemaciclib.
  • Other severe and/or uncontrolled acute or chronic medical or psychiatric condition or laboratory abnormality that, in the judgment of the investigator, may increase the risk associated with study participation or may interfere with the interpretation of study results and would make the patient inappropriate for this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea.)
  • Secondary malignancy requiring active treatment. Past history of malignancy other than prostate cancer treated with curative intent and not requiring additional treatment may be eligible after discussion with PI.
  • Patients with active autoimmune disease and history of inflammatory bowel disease. Brachytherapy boost will not be permitted.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04298983

Layout table for location contacts
Contact: Eddy Yang, MD, PhD (205) 934-5670 shyang@uabmc.edu

Layout table for location information
United States, Alabama
University of Alabama at Birmingham (UAB) Recruiting
Birmingham, Alabama, United States, 35249
Contact: Eddy Yang, MD, PhD       shyang@uabmc.edu   
Sponsors and Collaborators
University of Alabama at Birmingham
Layout table for investigator information
Principal Investigator: Eddy Yang, MD, PhD University of Alabama at Birmingham (UAB)
Layout table for additonal information
Responsible Party: Eddy Yang, Principal Investigator, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT04298983    
Other Study ID Numbers: IRB-300004706
First Posted: March 6, 2020    Key Record Dates
Last Update Posted: March 21, 2022
Last Verified: March 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Eddy Yang, University of Alabama at Birmingham:
androgen deprivation therapy
radiation therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs